Efficacy of humanized carbapenem exposures against New Delhi Metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3936-3940

  Wiskirchen, Dora E ^a   Nordmann, Patrice ^b   Crandon, Jared L ^c   Nicolau, David P ^c  

^a UNIVERSITY OF SAINT JOSEPH   (United States)

^b BICÊTRE HOSPITAL   (France)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEMASE; DORIPENEM; ERTAPENEM; METALLO BETA LACTAMASE; NEW DELHI METALLO BETA LACTAMASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; IMMUNOCOMPETENCE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; TIME FACTORS;

EID: 84880317088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00708-13     Document Type: Article

References (30)

1. Nordmann P, Poirel L, Toleman MA, Walsh TR. 2011. Does broadspectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66:689-692.
2. Bonomo RA. 2011. New Delhi metallo-lactamase and multidrug resistance: a global SOS? Clin. Infect. Dis. 52:485-487.
3. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol. 19:588-595.
4. Poirel L, Ros A, Carricajo A, Berthelot P, Pozzetto B, Bernabeu S, Nordmann P. 2011. Extremely drug-resistant Citrobacter freundii identified in a patient returning from India and producing NDM-1 and other carbapenemases. Antimicrob. Agents Chemother. 55:447-448.
5. Savard P, Gopinath R, Zhu W, Kitchel B, Rasheed JK, Tekle T, Roberts A, Ross T, Razeq J, Landrum BM, Wilson LE, Limbago B, Perl TM, Carroll KC. 2011. First NDM-positive Salmonella sp. strain indentified in the United States. Antimicrob. Agents Chemother. 55:5957-5958.
6. Karthikeyan K, Thirunarayan MA, Krishnan P. 2010. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii in India. J. Antimicrob. Chemother. 65:2253-2254.
7. Boulanger A, Naas T, Fortineau N, Figueiredo S, Nordmann P. 2012. NDM-1-producing Acinetobacter baumannii from Algeria. Antimicrob. Agents Chemother. 56:2214-2215.
8. Hu H, Hu Y, Pan Y, Liang H, Wang H, Wang X, Hao Q, Yang X, Yang X, Xiao X, Luan C, Yang Y, Cui Y, Yang R, Gao G, Song Y, Zhu B. 2012. Novel plasmid and its variant harboring both a blaNDM-1 gene and type IV secretion system in clinical isolates of Acinetobacter lwoffii. Antimicrob. Agents Chemother. 56:1698-1702.
9. Krizova L, Bonnin RA, Nordmann P, Nemec A, Poirel L. 2012. Characterization of a multidrug-resistant Acinetobacter baumannii strain carrying the blaNDM-1 and blaOXA-23 carbapenemase genes from the Czech Republic. J. Antimicrob. Chemother. 67:1550-1552.
10. Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, Kojic M. 2011. Emergence of NDM-1 metallo-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob. Agents Chemother. 55:3929-3931.
11. Lascols C, hackle M, Marshall SH, Juher AM, Bouchillon S, Badal R, Hoban D, Bonomo RA. 2011. Increasing prevalence and dissemination of NDM-1 metallo-lactamase in India: data from the SMART study (2009). J. Antimicrob. Chemother. 66:1992-1997.
12. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602.
13. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441-3443.
14. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nordmann P. 2012. NDM-1-producing Klebsiella pneumoniae now in Turkey. Antimicrob. Agents Chemother. 56:2784-2785.
15. Chan HLW, Poon LM, Chan SG, Teo JWP. 2011. The perils of medical tourism: NDM-1 positive Eschericia coli causing febrile neutropenia in a medical tourist. Singapore Med. J. 52:299-302.
16. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. 2011. New Delhi metallo-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg. Infect. Dis. 17:103-106.
17. Merck & Co Inc. 2011. Invanz (ertapenem for injection) product information. Merck & Co., Inc., Whitehouse Station, N. J.
18. Ortho-McNeil-Janssen Pharmaceuticals Inc. 2007. Doribax (doripenem for injection). Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, N. J.
19. Girlich D, Poirel L, Carattoli A, Kempf I, Lartigue MF, Bertini A, Nordmann P. 2007. Extended-spectrum-lactamase CTX-M-1 in Escherichia coli isolates from healthy poultry in France. Appl. Environ. Microbiol. 73:4681-4685.
20. Choi KH, Kumar A, Schweizer HP. 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64:391-397.
21. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
22. Deryke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-lactamase- producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486.
23. Xuan D, Banevicius MA, Capitano B, Kim MK, Nightingale C, Nicolau DP. 2002. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. 46:2990-2995.
24. DeRyke CA, Nicolau DP. 2007. Is all free time above the minimum inhibitory concentration the same: implications for-lactam in vivo modeling. Int. J. Antimicrob. Agents 29:341-343.
25. Bulik CC, Nicolau DP. 2010. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemaseproducing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54: 4112-4115.
26. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efficacy of 1-and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352.
27. Wiskirchen DE, Crandon JL, Nicolau DP. 2013. Impact of various conditions on the efficacy of dual carbapenem therapy against KPCproducing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 41:582-585.
28. Daikos GL, Markogiannakis A. 2011. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clinical Microbiol. Infect. 17:1135-1141.
29. Tumbarello M, Pierluigi V, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55:943-950.
30. Giamarellou H, Galani L, Baziaka F, Karaiskos I. 2013. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase- producing pandrug-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57:2388-2390.